Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2023-11-14 | Reverse | 1:10 |
MDxHealth SA is a global precision diagnostics company offering non-invasive prostate cancer genomic tests like SelectMDx and ConfirmMDx to help physicians identify clinically significant cancer while reducing invasive procedures.

The ExoDx Prostate Test is a non-invasive urine-based genomic assay, acquired in 2025, that aids physicians in assessing high-grade prostate cancer risk to guide biopsy decisions, enhancing MDxHealth’s urology diagnostics portfolio.
| Icon | PRODUCT | FY2022 | FY2023 |
|---|---|---|---|
![]() | Services Member | $36.97M | $69.97M ▲ |
| Map | REGION | FY2022 | FY2023 |
|---|---|---|---|
![]() | America Member | $36.77M | $69.71M ▲ |
![]() | Europe | $277K | — |
Overall rating: C
| PEER | PRICE | |
|---|---|---|
ACRS | $6.16 | COMPARE |
ASMB | $36.76 | COMPARE |
ZURA | $6.18 | COMPARE |
NEO | $17.33 | COMPARE |
SI | $20.34 | COMPARE |
XGN | $7.54 | COMPARE |
IMRX | $4.91 | COMPARE |
QTRX | $2.65 | COMPARE |